Top Markets
Coin of the day
D. Western Therapeutics Institute, Inc. D. Western Therapeutics Institute, Inc.

D. Western Therapeutics Institute, Inc.

4576
Rank in Stocks #27474
D. Western Therapeutics Institute, Inc. is a biotechnology enterprise focused... D. Western Therapeutics Institute, Inc. is a biotechnology enterprise focused on the research, discovery, and innovation of various pharmaceutical drugs. The company's current portfolio includes GLANATEC and GLA-ALPHA, ophthalmic solutions prescribed for glaucoma and ocular hypertension, as well as DW-1001, another medication for eye conditions. It also provides DWR-2206, a regenerative cell-based product targeting bullous keratopathy, and DW-1002, an ophthalmic surgical aid used for staining membranes like ILM, ALC, ERM, and PVR during cataract operations. In its development pipeline, the company is advancing DW-5LBT, a lidocaine patch designed to alleviate neuropathic pain post-shingles. Additionally, K-321 is progressing through Phase III clinical trials for Fuch endothelial corneal dystrophy, and H-1337, a multi-kinase inhibitor, has commenced Phase IIb trials for glaucoma and ocular hypertension treatment. The firm was established in 1999 and operates from its headquarters in Nagoya, Japan.
Share Price
$0.57414457
Market Cap
$33.00M
Change (1 day)
4.76%
Change (1 year)
-23.09%
Country
JP
Trade D. Western Therapeutics Institute, Inc. (4576)

Category

P/B ratio for D. Western Therapeutics Institute, Inc. (4576)
P/B ratio as of 2026 TTM: 0
According to D. Western Therapeutics Institute, Inc. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for D. Western Therapeutics Institute, Inc. from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
6.3419 -
US
3.7087 -
US
6.2413 -
NL
2.5054 -
AU
- -
CH